Wizz Air to Slash A321XLR Order and Focus on ‘Benign Markets'
European ultra low-cost carrier Wizz Air plans to cut its order for Airbus A321XLR jets by more than 70%, raising doubts about the long-range aircraft's fit with its business model.
The move was disclosed Thursday as Wizz reported weaker-than-expected earnings for the April-June quarter, citing ongoing engine issues that continue to sideline aircraft and drag on performance.
The company currently has a commitment for 47 of the 'Xtra Long Range' jets, but it hopes to reduce this to between 10 and 15 aircraft, describing it as a 'right-sizing' decision. It remains unclear how many of the surplus orders will be converted into shorter-range variants.
The mood music has already shifted since the airline accepted its first XLR in May. Speaking at the time, Owain Jones, Wizz Air chief corporate officer, described the delivery as a 'defini
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 minutes ago
- Yahoo
SPIE - Press release - 2025 Half-Year results
Consistent delivery of SPIE's growth modelYet another margin step-up: 2025 outlook firmed up Solid first-half results combining 40 bps margin step-up and 5.8% revenue growth Revenue: €4,979m, up +5.8% vs. H1 2024, including +3.8% growth from acquisitions and +2.4% organic growth Sequential improvement in organic growth: +2.6% in Q2, after +2.1% in Q1 Another step-up in EBITA margin: +40 bps to 6.0% in H1 2025 EBITA up +13.2% to €301m Adjusted net income: €166.6m (+5.7% vs. H1 2024) Sustained bolt-on M&A activity, reinforcing leadership in attractive markets 3 bolt-on acquisitions signed in 2025 to date, representing €96 million in annual revenue Further expansion into attractive Polish Building Solutions market and high-growth fiber optic services in Switzerland Robust pipeline on highly fragmented markets Strong financial structure, highly cash-generative model Leverage significantly reduced to 1.9x at end June 2025 from 2.4x at end June 2024 supported by outstanding working capital performance Successful €600 million sustainability-linked bond issuance in May 2025 (5-year maturity/ 3.75% coupon), reflecting SPIE's strong credit quality Anti-dilutive share buy-back implemented in Q1 for €39 million Interim cash dividend of €0.30 per share, i.e. 30% of the approved dividend for 2024, on September 18th, 2025 2025 margin outlook firmed up Strong total growth pushing revenue well above the €10 billion mark, including further organic growth and active bolt-on M&A Continued expansion of EBITA margin to at least 7.6% Gauthier Louette, Chairman & CEO, commented: 'SPIE's first-half results confirm the strengths of our model, the relevance of our strategy and the quality of our execution. Energy transition and digital transformation are firmly anchored as lasting growth drivers across our markets, allowing us to confidently navigate the current geopolitical and macroeconomic uncertainty. Thanks to our core focus on margin and financial discipline, we delivered once again a double-digit increase in EBITA. We kept a steady course in terms of bolt-on M&A, with all integration processes progressing well and three new acquisitions, focused on high-growth sectors. With rock-solid fundamentals, enhanced profitability and a disciplined approach to growth, SPIE is on track to meet its firmed-up 2025 targets and to continue creating long-term value.'About SPIE SPIE is the independent European leader in multi-technical services in the areas of energy and communications. The Group's 55,000 employees are committed to the decarbonisation of the economy, supporting the energy transition and responsible digital Group achieved in 2024 consolidated revenue of €9.9 billion and consolidated EBITA of €712 million. SPIE - 2025 Half-Year results - Press ReleaseError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
6 minutes ago
- Yahoo
Ipsen delivers strong results in the first half of 2025 and upgrades its full-year guidance
H1 total sales growth of 11.4% at CER1, or 9.7% as reported, driven by the three therapeutic areas: 95.7% in Rare Disease, 9.7% in Neuroscience, and 6.4% in Oncology H1 core operating income of €656m, growing by 21.9% as reported, with a core operating margin of 36.0% of total sales, increasing by 3.6 points Upgraded FY 2025 financial guidance2: total-sales growth greater than 7.0% at CER (prior guidance: greater than 5.0% at CER); core operating margin greater than 32.0% of total sales (prior guidance: greater than 30%) Pipeline progression including regulatory filing of tovorafenib in Europe, and initiation of a Phase II trial of LANT3 (IPN10200) in cervical dystonia European Commission approval on 23 July 2025 of Cabometyx® in advanced neuroendocrine tumors (NETs), the sixth indication Key upcoming milestones with the pivotal FALKON trial results for fidrisertib in FOP4 and the Proof-of-Concept data readout for the LANT in aesthetics PARIS, FRANCE, 31 July 2025 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-carebiopharmaceutical company, today presents its financial results for the first half of 2025. Extract of consolidated results H1 2025 H1 2024 % change €m €m Actual CERTotal Sales 1,819.8 1,659.3 9.7% 11,4 % Core Operating Income 655.8 538.0 21.9%Core operating margin 36.0% 32.4% +3.6ptsCore Consolidated Net Profit 508.3 399.4 27.3%Core earnings per share (fully diluted) €6.07 €4.78 27.0%IFRS Operating Income 451.6 317.8 42.1%IFRS operating margin 24.8% 19.2% +5.7ptsIFRS Consolidated Net Profit 335.5 232.3 44.4%IFRS earnings per share (fully diluted) €4.00 €2.78 44.0%Free Cash Flow 483.2 393.5 22.8%Closing Net cash / (Debt) 487.6 (6.8) n/a'Our half year results reflect continued strong momentum, with growth across all three therapeutic areas, particularly in our rare liver disease franchise, which is expanding rapidly and progressing well,' said David Loew, Chief Executive Officer, Ipsen. 'Building on that performance, I am pleased to increase our full year guidance in terms of sales and profitability.' 'I'm also delighted to report robust progression in our pipeline and portfolio, including the recent European Commission approval of Cabometyx® in advanced neuroendocrine tumors, an area where Ipsen has a strong legacy. In the second half of the year, we are anticipating the readout of our pivotal study of fidrisertib in fibrodysplasia ossificans progressiva and the proof-of-concept trial of our long-acting neurotoxin in aesthetics. Our focused strategy, our culture of excellence in execution and our commitment to science with purpose position us to provide a positive impact for patients and society.' Full-year 2025 guidance Based on the strong performance in the first half, Ipsen upgrades its financial guidance for 2025: Total-sales growth greater than 7.0%, at CER. Based on the average level of exchange rates in June 2025, an adverse impact on total sales of around 2% from currencies is expected Core operating margin greater than 32.0% of total sales, which includes additional R&D expenses from anticipated early and mid-stage external-innovation opportunities Guidance includes a negative impact on Somatuline sales due to a potential increased generic competition in the U.S. and Europe. It excludes any impact from potential late-stage (Phase III clinical development or later) business development transactions. Pipeline update since Q1 2025 In May 2025, Ipsen presented data on Iqirvo® (elafibranor) from the Phase II ELMWOOD study at the European Association for the Study of the Liver congress. It showed a favorable safety profile and demonstrated dose-dependent efficacy over 12 weeks for people living with PSC5, a rare liver disease with no approved treatment options. In June 2025, Ipsen initiated a Phase II study of LANT (IPN10200), in cervical dystonia. This marked the fourth study in the global long-acting neurotoxin development plan in therapeutics and aesthetics indications. On 23 July 2025, Ipsen received European Commission approval for Cabometyx® (cabozantinib) in previously treated advanced neuroendocrine tumors. This approval was based on positive outcomes from the Phase III CABINET trial. Consolidated financial statements The Board of Directors approved the condensed consolidated financial statements on 30 July 2025. The Company's auditors performed a limited review of the H1 2025 condensed consolidated financial statements. The interim financial report, with regards to the regulated information, will be available on in due course, under the Reports and Accounts tab in the Investor Relations section. Conference call A conference call and webcast for investors and analysts will begin today at 1pm CET. Participants can access the call and its details by registering here; webcast details can be found here. Calendar Ipsen intends to publish its year-to-date and third-quarter sales update on 22 October 2025. Notes All financial figures are in € millions (€m). The performance shown in this announcement covers the six-month period to 30 June 2025 (H1 2025) and the three-month period to 30 June 2025 (Q2 2025), compared to the six-month period to 30 June 2024 (H1 2024) and the three-month period to 30 June 2024 (H1 2024), respectively, unless stated otherwise. Commentary is based on the performance in H1 2025, unless stated IPSEN We are a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience. Our pipeline is fueled by external innovation and supported by nearly 100 years of development experience and global hubs in the U.S., France and the U.K. Our teams in more than 40 countries and our partnerships around the world enable us to bring medicines to patients in more than 80 countries. Ipsen is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information, visit CONTACTS Khalid Deojee +33 6 66 01 95 26 Sally Bain +1 857 32 00 517Anne Liontas +33 7 67 34 72 96 1 At constant exchange rates (CER), which exclude any foreign-exchange impact by recalculating the performance for the relevant period by applying the exchange rates used for the prior period.2 Excluding any impact from potential late-stage (Phase III clinical development or later) external-innovation transactions.3 Long-acting neurotoxin.4 Fibrodysplasia ossificans progressiva.5 Primary sclerosing cholangitis Attachment Ipsen - H1 2025 results announcementSign in to access your portfolio
Yahoo
6 minutes ago
- Yahoo
Credit Agricole Q2 earnings beat estimates on U.S. capital gain
By Mathieu Rosemain PARIS (Reuters) -Credit Agricole SA, France's second-largest listed bank, reported higher than expected quarterly earnings on Thursday, boosted by a one-time capital gain and stronger results at its insurance and investment banking units. Net income over the three months to June advanced 31% from a year earlier to 2.39 billion euros ($2.73 billion), beating the 2.03 billion average of a company-compiled analyst consensus. The surge was largely due to the deconsolidation of the U.S. division of Amundi, Credit Agricole's listed asset management arm. Amundi, Europe's largest fund manager, agreed last year to exchange its U.S. business for an up to 26% stake in Nasdaq-listed asset manager Victory Capital, resulting in the one-time, non-monetary capital gain of 453 million euros. Second-quarter revenues were up 3.1% to 7 billion euros, broadly in-line with expectations. Credit Agricole's insurance division delivered results nearly 13% higher, while its investment banking arm also supported earnings with growth of almost 7%. However, earnings at the bank's French retail unit declined, dragged down by a 3.4% drop in net interest income for the period, unlike rivals Societe Generale and BNP Paribas, which both reported higher NII in the country. NII also fell in Italy, Credit Agricole's second-biggest market after France, by 4.4%. The listed entity of Credit Agricole Group, which comprises 39 regional banks, has been embroiled in the wave of Italian banking consolidation in recent months by becoming Banco BPM's largest shareholder. BPM has been a takeover target for Italy's UniCredit, which recently dropped its bid. The French lender recently asked the European Central Bank if it could increase its stake in BPM above a 20% threshold, while ruling out that it would takeover the Italian bank. "This is an operation to clarify the accounts. Beyond that, BPM remains an important industrial partner for the group," CEO Olivier Gavalda told reporters. Credit Agricole achieved its 2025 targets a year head of schedule thanks to record results in 2024, leaving several analysts asking to hear more about the group's next plan. The French lender said it would present it's next medium-term plan on Nov. 18. ($1 = 0.8752 euros) 擷取數據時發生錯誤 登入存取你的投資組合 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤
